Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474814 | 0.83 | — | — | |
| SCHEMBL16633158 | 0.82 | KDM1A (0.44) | KDM1ALIPGCNR2CA12CA1 | |
| SCHEMBL31120953 | 0.81 | KDM4E (0.32) | KDM4EMAPK1HIF1ATSHR | |
| SCHEMBL31120943 | 0.80 | MEN1 (0.43) | KDM1ALIPGCNR2CA12CA1 | |
| SCHEMBL20982777 | 0.80 | KDM1A (0.43) | KDM1ALIPGCNR2CA12CA1 | |
| SCHEMBL1521342 | 0.79 | KDM4E (0.37) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL10642267 | 0.77 | KDM4E (0.36) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL18519508 | 0.77 | — | — | |
| SCHEMBL1521749 | 0.77 | KDM4E (0.36) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL9816683 | 0.76 | KDM1A (0.36) | KDM1ACNR2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118401517-A | PLpro inhibitors | 上海华汇拓医药科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| US-9321773-B2 | Compounds | Respivert, Ltd. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-9321773-B2 | Compounds | Respivert, Ltd. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| EP-2491037-B1 | QUINAZOLIN-4(3H)-ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| EP-2491037-A1 | COMPOUNDS | Respivert Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264583-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | KDM1A 2979/4885KDM4E 3332/4885MAPK1 3218/4885 |
| US-20140249164-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | KDM1A 2979/4885KDM4E 3332/4885MAPK1 3218/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | KDM1A 2979/4885KDM4E 3332/4885MAPK1 3218/4885 |
| US-20180118754-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | KDM1A 2979/4885KDM4E 3332/4885MAPK1 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.